These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 2875752

  • 1. Antilymphocytic antibodies and marrow transplantation. VIII. Recipient conditioning with Clq-affine monoclonal anti-pan T antibodies prevents GVHD in homozygous fully mismatched mice.
    Thierfelder S, Kummer U, Schuh R, Mysliwietz J.
    Blood; 1986 Oct; 68(4):818-24. PubMed ID: 2875752
    [Abstract] [Full Text] [Related]

  • 2. Antilymphocytic antibodies and marrow transplantation. IX. T-cell depletion in marrow donors with C1q high and low affinity antibodies for suppression of GVHD in fully mismatched mice.
    Antica M, Hoffmann-Fezer G, Thierfelder S.
    Exp Hematol; 1989 Oct; 17(9):942-7. PubMed ID: 2570711
    [Abstract] [Full Text] [Related]

  • 3. Antilymphocytic antibodies and marrow transplantation. VII. Two of nine monoclonal anti-Thy-1 antibodies used for pretreatment of donor marrow suppressed graft-versus-host reactions without added complement.
    Thierfelder S, Cobbold S, Kummer U, Waldmann H, Schuh R.
    Exp Hematol; 1985 Oct; 13(9):948-55. PubMed ID: 2864278
    [Abstract] [Full Text] [Related]

  • 4. Antilymphocytic antibodies and marrow transplantation. XIV. Antibody-induced suppression of graft-versus-host disease in C3-decomplemented mice differentiates two T-cell-depletion pathways.
    Thierfelder S, Mysliwietz J, Hoffmann-Fezer G, Kummer U.
    Blood; 1991 May 15; 77(10):2285-91. PubMed ID: 2029584
    [Abstract] [Full Text] [Related]

  • 5. Antilymphocytic antibodies and bone marrow transplantation. XI. Evidence that reduced Thy-1 expression in Thy-1.1 mice prevents suppression of graft-versus-host disease with anti-Thy-1 monoclonal antibodies.
    Mysliwietz J, Thierfelder S, Hoffmann-Fezer G, Kummer U.
    Transplantation; 1990 Apr 15; 49(4):749-55. PubMed ID: 1970200
    [Abstract] [Full Text] [Related]

  • 6. Neutralization of immunosuppression by antibodies against variable as well as constant regions of monoclonal anti-Thy-1 xenoantibodies and their ability to be suppressed by initial T cell depletion.
    Kremmer E, Thierfelder S, Kummer U, Lederer R, Mysliwietz J.
    Transplantation; 1989 Apr 15; 47(4):641-6. PubMed ID: 2468195
    [Abstract] [Full Text] [Related]

  • 7. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression.
    Knulst AC, Tibbe GJ, Noort WA, Bril-Bazuin C, Benner R, Savelkoul HF.
    Bone Marrow Transplant; 1994 Mar 15; 13(3):293-301. PubMed ID: 8199571
    [Abstract] [Full Text] [Related]

  • 8. Antilymphocytic antibodies and marrow transplantation. XII. Suppression of graft-versus-host disease by T-cell-modulating and depleting antimouse CD3 antibody is most effective when preinjected in the marrow recipient.
    Mysliwietz J, Thierfelder S.
    Blood; 1992 Nov 15; 80(10):2661-7. PubMed ID: 1358260
    [Abstract] [Full Text] [Related]

  • 9. Antigen density on target cells determines the immunosuppressive potential of rat IgG2b monoclonal antibodies.
    Kummer U, Thierfelder S, Mysliwietz J.
    Eur J Immunol; 1990 Jan 15; 20(1):107-12. PubMed ID: 1968387
    [Abstract] [Full Text] [Related]

  • 10. In vivo immunosuppression by pan-T cell antibodies relates to their isotype and to their C1q uptake.
    Kummer U, Thierfelder S, Hoffmann-Fezer G, Schuh R.
    J Immunol; 1987 Jun 15; 138(12):4069-74. PubMed ID: 2884259
    [Abstract] [Full Text] [Related]

  • 11. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
    Drobyski WR, Majewski D.
    Blood; 1996 Jun 15; 87(12):5355-69. PubMed ID: 8652851
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation.
    Truitt RL, Atasoylu AA.
    Blood; 1991 Jun 01; 77(11):2515-23. PubMed ID: 2039833
    [Abstract] [Full Text] [Related]

  • 18. Influence of the additional injection of host-type bone marrow on the immune tolerance of minor antigen-mismatched chimeras: possible involvement of double-negative (natural killer) T cells.
    Sefrioui H, Billiau AD, Overbergh L, Rutgeerts O, Waer M.
    Transplantation; 1999 Nov 27; 68(10):1560-7. PubMed ID: 10589955
    [Abstract] [Full Text] [Related]

  • 19. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance.
    Cobbold SP, Martin G, Qin S, Waldmann H.
    Nature; 1999 Nov 27; 323(6084):164-6. PubMed ID: 3528866
    [Abstract] [Full Text] [Related]

  • 20. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
    Mapara MY, Pelot M, Zhao G, Swenson K, Pearson D, Sykes M.
    Biol Blood Marrow Transplant; 2001 Nov 27; 7(12):646-55. PubMed ID: 11787527
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.